e-learning
resources
ERJ
2010
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis
Lorgelly P. K., Atkinson M., Lakhanpaul M., Smyth A. R., Vyas H., Weston V., Stephenson T.
Source:
Eur Respir J 2010; 35: 858-864
Journal Issue:
April
Disease area:
Paediatric lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lorgelly P. K., Atkinson M., Lakhanpaul M., Smyth A. R., Vyas H., Weston V., Stephenson T.. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. Eur Respir J 2010; 35: 858-864
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004
Intravenous steroids in the treatment of community-acquired pneumonia (CAP)
Source: Eur Respir J 2004; 24: Suppl. 48, 50s
Year: 2004
Efficacy of sequential intravenous (
i.v.
) to oral (
p.o.
) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to
m. pneumoniae
or
chlamydia
spp.
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Oral antibiotics prior to hospitalisation for community-acquired pneumonia
Source: Eur Respir J 2008; 31: 478-479
Year: 2008
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma
Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues
Year: 2015
Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment
Source: Annual Congress 2009 - Pulmonary infections
Year: 2009
Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP)
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France
Source: Eur Respir J 2003; 22: Suppl. 45, 151s
Year: 2003
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Fluoroquinolone
versus
β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Meta analysis of hospitalized patients with community-acquired pneumonia (CAP) treated with levofloxacin
Source: Eur Respir J 2004; 24: Suppl. 48, 188s
Year: 2004
Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011
The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept